Catalysts for $REGN
73 tracked
Nov 6, 2018
approval
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Oct 19, 2018
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
Sep 28, 2018
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Aug 22, 2018
approval
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Jul 20, 2018
approval
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Apr 10, 2018
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
Jan 10, 2018
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
Sep 20, 2017
approval
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Jul 27, 2017
approval
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Apr 24, 2017
approval
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Mar 28, 2017
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
Jul 24, 2015
approval
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
RECRUITING
phase readout
NCT06616584: Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
REGENERON PHARMACEUTICALS, INC.
→